Definium Therapeutics (DFTX) stock
DFTX · Definium Therapeutics Inc. · NASDAQ
What is the latest news on DFTX stock?
DFTX fell 3.78% to $28.34 on Nov 20, 2026. No DFTX story in the last two days; the most recent is below.
SCHEDULE 13G - Definium Therapeutics, Inc. (0001813814) (Subject)
All DFTX newsWhen does Definium Therapeutics report earnings?
Definium Therapeutics last reported on Nov 9, 2026, the date it announced on Oct 29, 2026. Before that it reported on Aug 6, 2026 and May 7, 2026. On that schedule the next report would come around early February 2027, with the date usually announced about 1 week ahead.
DFTX earnings historyWho owns the most DFTX stock?
BlackRock, Inc. was the largest reported holder of DFTX at the end of Q2 2026, with 11,232,834 shares worth $528.4 million. Next came Avoro Capital Advisors LLC ($338.2 million) and Driehaus Capital Management LLC ($322.0 million). In all, 360 institutions reported $5.3 billion of DFTX in their 13F filings.
All DFTX fund holdersAre insiders buying or selling DFTX?
Insiders are selling. In the last 90 days 5 insiders sold $3.0 million of DFTX in trades reported on Form 4. The latest: Daniel Karlin sold $397K, reported on Sep 30, 2026.
DFTX insider tradesFinancial highlights
Full financials- Net income, TTM
- -$337.48M
- Cash
- $241.15M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
Latest news
25 items- 13D/GSEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.SCHEDULE 13G - Definium Therapeutics, Inc. (0001813814) (Subject)
- 13D/GSEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.SCHEDULE 13G - Definium Therapeutics, Inc. (0001813814) (Subject)
- SECSEC Form 10-Q filed by Definium Therapeutics Inc.10-Q - Definium Therapeutics, Inc. (0001813814) (Filer)
- SECDefinium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Definium Therapeutics, Inc. (0001813814) (Filer)
- PRDefinium Therapeutics Reports Third Quarter 2026 Financial Results and Recent HighlightsReported positive topline Phase 3 results from two Phase 3 studies of DT120 ODT in generalized anxiety disorder (GAD) Received FDA Breakthrough Therapy Designation for DT120 ODT in major depressive disorder (MDD) On track for DT120 ODT NDA filing in first half of 2027 DT402 demonstrated positive initial results in a Phase 2a trial in adults with autism spectrum disorder (ASD); clinical study evaluating multiple dosing paradigms planned for 2027 Approximately $1.05 billion in cash, cash equivalents, and investments as of September 30, 2026 Conference call scheduled today at 4:30 p.m. EST Definium Therapeutics, Inc. ("Definium" or the "Company") (NASDAQ:DFTX), a late-stage clinica
- PRDefinium Therapeutics Announces New Employee Inducement GrantsDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to ten newly hired non-executive employees consisting of options to purchase an aggregate of 269,800 common shares of the Company (the "Options") with effective grant dates of November 9, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant a
- 13D/GSEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.SCHEDULE 13G - Definium Therapeutics, Inc. (0001813814) (Subject)
- PRDefinium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall CongressFirst-ever comprehensive presentation of DT120 clinical program to date including positive topline data from Panorama, Emerge and Voyage Phase 3 studies New robust compilation of safety data across the three Phase 3 studies also to be presented Definium Therapeutics, Inc. (NASDAQ:DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced four poster presentations at the 2026 NEI Fall Congress taking place November 5 through 8 in Colorado Springs, CO. Positive topline results from Panorama, the Company’s second Phase 3 st
- PRDefinium Therapeutics to Participate at Upcoming Investor ConferencesDefinium Therapeutics, Inc. (NASDAQ:DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences: Stifel 2026 Healthcare Conference Fireside Chat Date and Time: Tuesday, November 10, 2026 at 9:20 AM ET Location: New York, NY Webcast Link: Stifel 2026 Healthcare Conference Jefferies Global Healthcare Conference in London Fireside Chat Date and Time: Tuesday, November 17, 2026 at 11:30 AM GMT Psychedelics Pane
- PRDefinium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026Definium Therapeutics, Inc. (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a webcast at 4:30 p.m. EST on Monday, November 9, 2026 to report financial results for the third quarter ended September 30, 2026, and discuss recent business highlights.Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the Definium Therapeutics website, ir.definiumtx.com, and
- PRDefinium Therapeutics Announces New Employee Inducement GrantsDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to six newly hired non-executive employees consisting of options to purchase an aggregate of 93,320 common shares of the Company (the "Options") with effective grant dates of October 26, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant an
- PRDefinium Therapeutics Announces New Employee Inducement GrantsDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 45,940 common shares of the Company (the "Options") with effective grant dates of October 13, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and
- ANALYSTAnalyst initiated coverage on Definium Therapeutics with a new price targetAnalyst initiated coverage of Definium Therapeutics with a rating of Overweight and set a new price target of $84.00
- INSIDERChief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- PRDefinium Therapeutics Announces New Employee Inducement GrantsDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to fifteen newly hired non-executive employees consisting of options to purchase an aggregate of 334,810 common shares of the Company (the "Options") with effective grant dates of September 28, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the g
- SECSEC Form 144 filed by Definium Therapeutics Inc.144 - Definium Therapeutics, Inc. (0001813814) (Subject)
- SECSEC Form 144 filed by Definium Therapeutics Inc.144 - Definium Therapeutics, Inc. (0001813814) (Subject)
- SECSEC Form 144 filed by Definium Therapeutics Inc.144 - Definium Therapeutics, Inc. (0001813814) (Subject)
- INSIDERDirector Vallone Carol A exercised 1,086 shares at a strike of $35.52, increasing direct ownership by 5% to 22,296 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERDirector Krebs Andreas exercised 1,629 shares at a strike of $35.52, increasing direct ownership by 8% to 21,402 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Executive Officer Barrow Robert was granted 750,000 shares, increasing direct ownership by 50% to 2,244,640 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
DFTX rankings
- Insider13(34%)
- Other12(32%)
- SEC Filings7(18%)
- 13D/G3(8%)
- Earnings2(5%)
- Analyst1(3%)
Definium Therapeutics Inc. (DFTX) is a Medicinal Chemicals and Botanical Products company listed on NASDAQ. In the last 30 days Quantisnow tracked 11 wire items for DFTX, including 4 press releases and news items, 3 13D/G filings and 2 earnings updates. The most recent was published Nov 16, 2026.
DFTX FAQ
7 questionsIs DFTX profitable?
No. Definium Therapeutics Inc. reported a net loss of $337.48M for the twelve months ended Sep 30, 2026.How much cash and debt does DFTX have?
Definium Therapeutics Inc. reported $241.15M in cash and cash equivalents and $36.66M of debt on its most recent balance sheet in SEC filings.Where does DFTX stock trade?
Definium Therapeutics Inc. (DFTX) is listed on NASDAQ.What sector and industry is DFTX in?
Definium Therapeutics Inc. operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.What are analysts saying about DFTX?
Definium Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight with a $84.00 price target on 2026-10-09. Recent price targets range from $25.00 to $84.00.What companies are similar to DFTX?
Notable peers in the same industry include SUPN (Supernus Inc.), LXRX (Lexicon Pharmaceuticals Inc.), NBIX (Neurocrine Biosciences Inc.), AXSM (Axsome Therapeutics Inc.). Compare DFTX side-by-side with any of them on Quantisnow.How can I track DFTX on Quantisnow?
Quantisnow aggregates Definium Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DFTX to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change